Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Items 501–597 of 597
Antigenicity and immunogenicity of SARS-CoV-2 surface glycoprotein fragment in CHO cells
Karimi, S., Nazarian, S., Sotoodehnejadnematalahi, F., Dorostkar, R., & Amani, J. (2023) · Iranian Journal of Microbiology · doi:10.18502/ijm.v15i1.11929 · Cited by 2
“It is the target of many neutralizing antibodies (4) and a target in vaccine design efforts (5).”
BackgroundGutlapalli, S. D., Ganipineni, V. D. P., Danda, S., Fabián, D., Okorie, I. J., Paramsothy, J., Kailayanathan, T., Umyarova, R., Aviles, C., Garlapati, S. K. P., et al. (2023) · Cureus · doi:10.7759/cureus.36809 · Cited by 3
“Furthermore, the most potent nAbs according to previous studies, are antibodies that target epitopes overlapping with the ACE 2 receptor binding site (RBS), divided into RBS A/class 1; RBS B, C, D/class 2 antibodies requiring minimal affinity maturation to neutralize the virus at very low concentrations (single digit…”
BackgroundDriouich, J., Cochin, M., Lingas, G., Lucıanı, L., Baronti, C., Bernadin, O., Gilles, M., Villarroel, P. M. S., Moureau, G., Petit, P.-R., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116988 · Cited by 2
Insights into biological therapeutic strategies for COVID-19
Tian, X., Li, C., Wu, Y., & Ying, T. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.02.001 · Cited by 2
Wang, S.-L., Wu, D.-H., Xiong, H.-L., Wang, J., Tang, Z., Chen, Z.-H., Wang, Y.-Z., Zhang, Y.-L., Ying, D., Lin, X., et al. (2021) · bioRxiv · doi:10.1101/2021.04.10.439161 · Cited by 2
“Moreover, many studies also have reported the same enrichment of VH3-53/66 mAbs targeting the antigenic sites similar to site S1, and find that they share structural similarities with each other by solving structures of immune complex with SARS-CoV-2 RBD (8, 29, 48-50).”
BackgroundAndreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.12.456077 · Cited by 2
Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J. G., Sandhu, J. K., Duque, D., Hewitt, M., Wen, S., Bavananthasivam, R., Beitari, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.20.473401 · Cited by 2
Immunity Escape of SARS-CoV-2 Variants: Omicron Leads the WayPreprint
Dhingra, R., Sharma, A., Balda, S., Billa, A., Sah, S. N., Capalash, N., & Sharma, P. (2022) · Preprints.org · doi:10.20944/preprints202203.0376.v1 · Cited by 1
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X. P., Yang, Z. Y., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-497595/v1 · Cited by 2
Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.625234 · Cited by 2
A highly divergent cryptic SARS-CoV-2 lineage exhibits strong receptor binding and immune evasionPreprint
Feng, Z., Teo, Q. W., Ibrahim, B. A., Liu, W., Zhang, D., Mao, K. J., Shao, E. K., Gregory, D. A., Wilson, I. A., Johnson, M. C., et al. (2025) · medRxiv · doi:10.1101/2025.11.18.25340485 · Cited by 2
Hamamichi, S., Uno, N., Shimoya, K., Fukushima, T., Abe, M., Watanabe, A., Ito, M., Wakasa, Y., Yajima, Y., Suzuki, R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.020 · Cited by 2
“35 Furthermore, we analyzed the IGHV segments from the splenic IgG+ B cells, and observed similar usages, such as IGHV3-33 , IGHV1-18 , and IGHV3-43 as top 3 commonly used segments (Figure S7A).”
Wan, Y.-H., Pernikoff, S., Aldridge, N. T., Lang, K., Dudley, H. M., Scharffenberger, S. C., Kher, G. M., Phipps, W. T., Pancera, M., Boonyaratanakornkit, J. B., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013772 · Cited by 1
“Indeed, reproducible classes of antibodies have been described for other pathogens including HIV-1 [59], SARS-CoV2 [60], RSV [61] and influenza [62].”
Wu, Q., Hu, H., Qin, L., Ma, X., Chen, B., Li, X., Chen, Y., Xing, L., Yang, M., Li, C., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01386-z · Cited by 1
“In contrast, the RS group showed enrichment for IGHV3-74 - IGHJ4 and IGHV3-53 - IGHJ4 , which have been implicated in B cell responses to SARS-CoV-2 antigens 69 and RBD-speci fi c neutralizing antibodies 70 , respectively.”
Fukunaga, Y., Saito-Sasaki, N., Ohta, E., & Sawada, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721035 · Cited by 1
“The mRNA vaccines against COVID-19 exert their potent immunogenicity through both the encoded spike protein and the adjuvant-like properties of lipid nanoparticles, stimulating innate immune responses and transiently disturbing immune tolerance in predisposed individuals (7).”
Hensel, R. C., Materón, E. M., Macedo, A. M. R. B., Raimundo, B. V. B., Kadowaki, M. A. S., Portuondo, D. L., Tavares, A. G., Penteado, L. D. A., Zanelli, C. F., Azevedo, R. B., et al. (2026) · Biomedical Microdevices · doi:10.1007/s10544-026-00799-w · Cited by 1
“CDR L1 and L3 have a small contribution to the hydrogen bonds with RBD (Wang et al. 2021; Yuan et al. 2020).”
Fu, Y., Feng, Z., Erickson, S. A., Halfmann, P., Li, L., Chervin, J. C., Troxell, C. A., Sun, J., Yasuhara, A., Changrob, S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117137 · Cited by 2
Chakraborty, A. K., Jayaraman, A., & Newton, D. (2026) · PRX Life · doi:10.1103/znt6-6n38 · Cited by 2
“The panels showing GC B cells as a function of time are results of computer simulations; data taken from Ref.”
Lv, H., Feng, Z., Teo, Q. W., Chen, C., Gopal, A. B., Choi, D., Tan, T. J. C., Tang, Y. S., Siu, L. Y.-L., Nourmohammad, A., et al. (2026) · Advanced Science · doi:10.1002/advs.76522 · Cited by 2
Linsen, L. I., Zhu, C., Zhao, X., & Qu, F. (2021) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2021.03022 · Cited by 1
Binding Strength and Hydrogen Bond Numbers between COVID-19 RBD and HVR of Antibody
Wang, R. T., Xu, F., Zhou, Q. X., Song, T., Xu, K. J., & Xu, G. (2021) · Crystals · doi:10.3390/cryst11080997 · Cited by 1
Magen, H., Avigdor, A., Nevo, L., Fried, S., Gibori, A., Levin, E. G., Lustig, Y., Shkury, E., & Rahav, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284925 · Cited by 1
“As not all antibodies against the RBD IgG are neutralizing [35], the NA response is clinically more meaningful than that of anti-RBD-IgG antibodies for preventing infection.”
BackgroundRencilin, C. F., Chatterjee, A., Ansari, M. Y., Deshpande, S., Mukherjee, S., Singh, R., Jayatheertha, S. B., Reddy, P. M., Hingankar, N. K., Varadarajan, R., et al. (2025) · RSC Advances · doi:10.1039/d5ra00373c · Cited by 3
“…neutralizing antibodies have been reported to broadly target three speci c sites in the S1 subunit: (a) the NTD region, 7,8 (b) the ACE2 binding surface of the RBD (blocking the S-ACE2 interaction) 9,10 and (c) rarely the N-linked glycans in RBD (without any in uence on S-ACE2 interaction).”
Beeckmans, S., & DRIESSCHE, E. V. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671923 · Cited by 2
“Using an in vitro assay, CR3022 proved to be neutralizing for SARS-CoV but not for SARS-CoV-2, though it is able to bind to its RBD, albeit with 100-fold lower affinity (Yuan et al., 2020a).”
BackgroundMethodInfluentialWang, S., Wu, Y., Wang, Y., Chen, Z., Dong, Y., Lin, X. M., Liu, C., Lin, M., Zhang, J., Zhu, Y., et al. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114597 · Cited by 1
“As antibodies derived from VH3–53/66 germline, display the native binding capability to SARSCoV-2 RBD, such class antibodies contribute to form immunodominance in SARS-CoV-2-infected patients (Yuan et al., 2020).”
A study protocol to prepare an RBD protein for vaccine against COVID-19
Jahangir, Z. S., & Marnik, A. H. (2022) · F1000Research · doi:10.12688/f1000research.54738.3 · Cited by 1
Innovative recombinant protein-based vaccines against SARS-CoV-2
Mosqueda, J., Hernández-Silva, D. J., Romero‐Maldonado, A., Mejia-López, S., & Mercado-Uriostegui, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00016-4 · Cited by 4
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humansPreprint
Castro, A., Ozturk, K., Zanetti, M., & Carter, H. (2020) · bioRxiv · doi:10.1101/2020.12.26.424449 · Cited by 1
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.446560 · Cited by 1
Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV virusesPreprint
Wang, H., Chen, Q., Hu, Y., Wu, X., Dai, L., Zhang, Y., Li, F., Lü, J., Chen, Y., & Liu, X. (2021) · Research Square · doi:10.21203/rs.3.rs-612103/v2 · Cited by 1
The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2Preprint
Allen, J., Ivory, D., Song, S. G., He, W.-T., Capozzola, T., Yong, P., Burton, D., Andrabi, R., & Crispin, M. (2022) · bioRxiv · doi:10.1101/2022.08.24.505118 · Cited by 2
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2231608/v1 · Cited by 1
Lack of ancestral SARS-CoV-2 imprinting promotes BA.3.2.2 infection in childrenPreprint
Niu, X., Xiong, D., He, P., Yu, L., Li, Y. L., Cai, X. L., An, R., Wang, Y., Kong, R., Yu, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.730251 · Cited by 1
Protective pan-betacoronavirus neutralizing antibodies by vaccinationPreprint
Zhou, P.-P., Feng, Z., He, W.-T., Zhu, Y., Yuan, M., Li, X., Zhang, Y., Vo, L., Capozzola, T., Callaghan, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743418 · Cited by 2
(2025) · doi:10.1016/j.antiviral.2025.106235 · Cited by 1
A novel coronavirus—from basic research to clinic
Luo, D., Wang, T., Tan, Z., Guo, S., Yu, Z., Liu, Y., ZHANG, Y., Wang, B., Gao, Y., Wang, H., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0233
Neutralizing response against E484K variant after original SARS-CoV-2 infectionPreprint
Hayashi, T., Yaegashi, N., & Konishi, I. (2021) · medRxiv · doi:10.1101/2021.05.07.21256803
Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV virusesPreprint
Wang, H., Chen, Q., Hu, Y., Wu, X., Dai, L., Zhang, Y., Li, F., Lü, J., Chen, Y., & Liu, X. (2021) · Research Square · doi:10.21203/rs.3.rs-612103/v1 · Cited by 1
Mémoire immunitaire contre le SARS-CoV-2
Reynaud, C., Weill, J., Chappert, P., & Mahévas, M. (2021) · médecine/sciences · doi:10.1051/medsci/2021122
Карягина, А. С., Gromov, A. V., Grunina, T. M., Lyashchuk, A. M., Av, G., Strukova, N. V., Generalova, M. S., Galushkina, Z. M., Soboleva, L. A., Dobrynina, O. Y., et al. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521100043
Why is 'City of Death' the Best Doctor Who Story?
McKee, A. (2007) · Manchester University Press eBooks · Cited by 2
Khatri, B. S., & Burt, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.23.473701
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471953
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14135138
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escapePreprint
Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.06.475303
Contractor, D., Globisch, C., Swaroop, S., & Jain, A. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484421
Antibody Response to SARS-CoV-2 Infection in Non Vaccinated Health Care Personnel
Khanam, P. A., Hassan, M. S., Alam, M. S., Belal, M. H., Rahman, Z. F., Begum, T., & Khan, A. (2022) · Journal of Bangladesh College of Physicians and Surgeons · doi:10.3329/jbcps.v40i3.60303
Rencilin, C. F., Ansari, M. Y., Chatterjee, A., Deshpande, S., Mukherjee, S., Singh, R., Jayatheertha, S. B., Reddy, P. M., Das, P., Hingankar, N. K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.03.518949
“5 of the RBD and RBM and those block S-ACE2 interaction (2, 19) and (c) rare ones that target N-linked glycans in RBD without any influence on S-ACE2 interaction (20), however demonstrated destabilizing”
BackgroundThe structure of the RBD–E77 Fab complex reveals neutralization and immune escape of SARS-CoV-2
Zhang, Z., Li, X., Xue, Y. W., Yang, B., Jia, Y., Liu, S., & Lu, D. (2023) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798323005041
Yasugi, M., Nakagama, Y., Kaku, N., Nitahara, Y., Hatanaka, N., Yamasaki, S., & Kido, Y. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.076
Yan, Q., Gao, X., Liu, B., Hou, R., He, P., Ma, Y., Zhang, Y., Zhang, Y., Li, Z., Chen, Q., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.12.561995
Li, Z., Obraztsova, A., Shang, F., Oludada, O. E., Malapit, J., Busch, K., van Straaten, M., Stebbins, C. E., Murugan, R., & Wardemann, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.01.569639
“3d,e) including antibodies with long HCDR3 17, 18 and IGHV3-53 or IGHV3-66 seg-209 ments paired with IGHJ6 that frequently encode high-affinity anti-RBD antibodies 19 (Fig.”
BackgroundGrados-Torrez, R. E., Callisaya, L. M. O., Torrez, P. B. R., Alanoca, A. A. C., Miranda, E. B. V., & Michel, A. V. (2023) · Gaceta Médica Boliviana · doi:10.47993/gmb.v46i2.777
Torrez, R. E. G., Callisaya, L. M. O., Torrez, P. B. R., Alanoca, A. A. C., Miranda, E. B. V., Argani, K. F. A., Chamizo, D. A. P., & Michel, A. V. (2023) · Gaceta Médica Boliviana · doi:10.47993/gmb.v46i2.664
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815705
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815708
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815702
Khaidarov, S., & Tulman, E. R. (2024) · Experimental biology · doi:10.26577/eb.2024.v99.i2.015 · Cited by 2
DEVELOPMENT OF NEUTRALIZING ANTIBODY ASSAYS: PITFALLS AND CHALLENGES
Ahmad, S., Farhana, Agnihotri, Y., Pratap, P. D., Anwar, S., & Saud, T. (2025) · International Journal of Research -GRANTHAALAYAH · doi:10.29121/granthaalayah.v13.i3.2025.5988
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.15.649027
Oda, A., Furukawa, S., Kitabatake, M., Ouji-Sageshima, N., Ito, T., Takahashi, R., Kawamura, T., Nakajima, Y., Shimonishi, N., Ogiwara, K., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2518-7157
“43 Anti-FVIII neutralizing antibodies target functional FVIII epitopes such as A2, A3, and C2, while non-neutralizing antibodies bind to nonfunctional FVIII regions.”
B Cell Epitope Mapping by High-Density Competition ELISAs
Vance, D. J., & Mantis, N. J. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4591-8_21 · Cited by 1
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.10.664240 · Cited by 1
Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting
Hu, Y., Hu, C., Su, J., Zhu, B., Liang, H., & Shao, Y. (2025) · Archives of Virology · doi:10.1007/s00705-025-06372-9 · Cited by 1
“6). indicating that C12 also targets the ‘up’ conformation of the RBD [40].”
InfluentialExplore antibody repertoire in the era of AI
Zhang, Y., Wang, H., Liu, C., & Meng, F. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025230
Additional file 1 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R.-M., Kuo, T.-W., Lin, Y., & Wu, H.-C. (2023) · Figshare · doi:10.6084/m9.figshare.23812506
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815699
Additional file 2 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R.-M., Kuo, T.-W., Lin, Y., & Wu, H.-C. (2023) · Figshare · doi:10.6084/m9.figshare.23812509
Li, L., Gao, M., Jiao, P., Zu, S., Deng, Y.-Q., Wan, D., Cao, Y., Duan, J., Aliyari, S. R., Li, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19783635
Niu, C., Huang, X., Yan, Q., Liu, B., Gao, X., Song, Y., Wang, J. Y., Wang, L., Li, Z., Zheng, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695307
Cui, T., Liu, S., Wang, T., Liu, Y., Liang, X., Chen, F., Huang, M., Su, X., Song, T., Su, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04505-0 · Cited by 1
Ayres, F., Lambson, B. E., Mkhize, N. N., Makhado, Z., Mhlanga, D., Serage, R., Moore, P. L., Wibmer, C. K., & Moyo-Gwete, T. (2026) · Structure · doi:10.1016/j.str.2026.01.006
Elucidating the Molecular Mechanism of 3D1 Antibody Binding to a Swine Enteric Coronavirus Antigen
Zhang, L. Q., Liang, Z., Yang, G., & Yan, L. (2026) · Viruses · doi:10.3390/v18020208
Park, S., Mischka, J., Okba, N. M. A., Abbad, A., Yuan, M., Srivastava, K., Gleason, C., Mulder, L. C. F., Copps, J., Saam, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706653 · Cited by 1
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Singh, G., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709398
Evaluating southern pigtail macaques as an immunological model for human antibody responses
Zoest, V. P., Lee, W. S., Esterbauer, R., Tan, H., Juno, J. A., & Wheatley, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-42695-6
Morozova, V., Prud, M. V., & Kyrychenko, A. V. (2025) · Kharkov University Bulletin Chemical Series · doi:10.26565/2220-637x-2025-45-02
Application of lentiviral vector in vaccinology
Ku, M. (2020) · theses.fr (ABES) · doi:10.70675/18309422z66eez4f9fz9b16zd621476d44cd
Strumilienė, E. (2026) · Pulmonology and allergology · doi:10.15388/vu.thesis.908
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137.1
Systems-Scale Structural Modeling Reveals the Germline Architecture of ImmunodominancePreprint
Shrock, E. L., Sun, E., Dhindsa, A., Witwer, M. H., Yu, Z., Ivanochko, D., Lee, I., Coventry, B., Gonzalez, M. B., Julien, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729678 · Cited by 1
Structural and functional mapping of protective human monoclonal antibodies against enterovirus A71
Zhou, D., Kotecha, A., Kelly, J. T., Huang, P.-N., Chen, Y., Walter, T. S., Duyvesteyn, H. M. E., Owens, R. J., Ho, S., Lin, T., et al. (2026) · Science Advances · doi:10.1126/sciadv.aee8217 · Cited by 1
“The structural convergence of neutralizing antibodies on common epitopes and the use of public gene families have been observed for viruses including SARS- CoV-2 ( 17 , 18 ), influenza ( 19 ), and Junín virus ( 33 ).”
Skelly, A. N., Fan, C., Keeffe, J. R., Ökten, A. B., Gavor, E., Newby, M. L., Allen, J. D., Kreider, E. F., Ding, W., Osbaldeston, R. A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536870123
“NAbs primarily target the S1 receptor binding domain (RBD), and six distinct RBD epitope classes have been defined: class 1, 2, 3, 4, 5, and 1/4 (9–14).”
Malek, R., Matassoli, F. L., Gordon, K., Shimberg, G. D., Mantus, G. E., Spangler, A., Chopde, A. J., Teng, I., Zhou, T., Lin, B. C., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aeb9847
Dixit, K., Nayak, K., Saini, M. K., Qamar, S., Bajpai, P., Reddy, E. S., Ameer, S., Dubey, V. D., Pervez, M., Kohli, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846926
Pianpaktr, P., Ramanandana, P., Nanthawong, S., Wongtangprasert, T., Saelao, P., Muanwien, P., Boonkrai, C., Cicek, H., Focht, D., Kimbung, Y. R., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153102
Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination
Han, X., Jiang, H. X., Zheng, H., Jin, P., Xu, L., Wang, F., Li, S. N., Shao, C., 贾斯月, Feng, J., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08620-1
Suryadevara, N., Zost, S. J., Powers, J. M., Dadonaite, B., Gilchuk, P., Binshtein, E., Scheaffer, S. M., Leist, S. R., Myers, L., Ravera, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.15.745004
Nilsson, P., Johansson, E., & Andersson, L. (2026) · Interdisciplinary Research in Medical Sciences Specialty · doi:10.51847/kcacqjdxol
Niu, C., Huang, X., Yan, Q., Liu, B., Gao, X., Song, Y., Wang, J., Wang, L., Li, Z., Zheng, H., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003996
Zhang, M., Wang, D., Xi, W., Jia, H., Shen, B., Wen, Y. F., Wang, J., & Feng, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1888170
Nanobody engineering for next-generation therapeutics
Handa, T., Agarwal, V., Kumar, R., Singla, J., & Tomar, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44536-1.00016-x
Lack of ancestral SARS-CoV-2 imprinting promotes Omicron sublineage BA.3.2.2 infection in children
Niu, X., Xiong, D., He, P., Yu, L., Li, Y., Cai, X., An, R., Wang, Y., Kong, R., Yu, Y., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02526-w
Sequencing of SARS-CoV-2 and Influenza Monoclonal Antibodies
Provided, N. P. N. (2026) · ImmPort · doi:10.21430/m3r4bhisfy
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.